Literature DB >> 29340802

Longitudinal trajectories of antidepressant use in pregnancy and the postnatal period.

Gretchen Bandoli1, Grace M Kuo2, Renu Sugathan3, Christina D Chambers4, Matthieu Rolland5, Kristin Palmsten6.   

Abstract

Studies of antidepressant safety in pregnancy typically do not address complex patterns of use throughout pregnancy. We performed longitudinal trajectory modeling to describe patterns of antidepressant use in the first 32 weeks of pregnancy, and test whether these trajectories are associated with a reduction in birth weight or gestational age at delivery. Our study included 166 pregnant women with deliveries between 2011 and 2015 who were prescribed an antidepressant between 91 days prior to last menstrual period and 32 weeks of gestation. From electronic medical records, we estimated average daily dose and cumulative dose per week for the first 32 weeks of gestation and for the first 13 weeks postnatal. We clustered women with similar utilization patterns using k-means longitudinal modeling and assessed the associations between trajectory group and birth weight and gestational age at delivery. We identified four cumulative dose trajectory groups and three average daily dose trajectory groups in each period. Relative to the lowest trajectory group, the highest trajectory group during pregnancy was associated with reduced birth weight in multivariable analysis (average daily highest trajectory vs. lowest trajectory β - 314.1 g, 95% CI - 613.7, - 15.5) adjusted for depression severity score, maternal age, race, and pregnancy smoking. Trajectory groups were not associated with gestational age at delivery. The highest trajectory group of antidepressant use in pregnancy was associated with a modest reduction in birth weight but not with gestational age at delivery. Longitudinal trajectories allow for a dynamic visualization and quantification of medication use among pregnant women.

Entities:  

Keywords:  Antidepressive agents; Birth outcomes; Methodology; Pharmacoepidemiology; Pregnancy

Mesh:

Substances:

Year:  2018        PMID: 29340802      PMCID: PMC6031455          DOI: 10.1007/s00737-018-0809-2

Source DB:  PubMed          Journal:  Arch Womens Ment Health        ISSN: 1434-1816            Impact factor:   3.633


  22 in total

1.  Increasing use of antidepressants in pregnancy.

Authors:  William O Cooper; Mary E Willy; Stephen J Pont; Wayne A Ray
Journal:  Am J Obstet Gynecol       Date:  2007-06       Impact factor: 8.661

Review 2.  The use of antidepressant medication in pregnancy.

Authors:  Shona Ray; Zachary N Stowe
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2013-10-11       Impact factor: 5.237

3.  KmL: a package to cluster longitudinal data.

Authors:  Christophe Genolini; Bruno Falissard
Journal:  Comput Methods Programs Biomed       Date:  2011-06-25       Impact factor: 5.428

4.  A cluster separation measure.

Authors:  D L Davies; D W Bouldin
Journal:  IEEE Trans Pattern Anal Mach Intell       Date:  1979-02       Impact factor: 6.226

5.  Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials.

Authors:  Yu Hayasaka; Marianna Purgato; Laura R Magni; Yusuke Ogawa; Nozomi Takeshima; Andrea Cipriani; Corrado Barbui; Stefan Leucht; Toshi A Furukawa
Journal:  J Affect Disord       Date:  2015-03-31       Impact factor: 4.839

6.  How to take into account exposure to drugs over time in pharmacoepidemiology studies of pregnant women?

Authors:  Caroline Hurault-Delarue; Cécile Chouquet; Nicolas Savy; Isabelle Lacroix; Anna-Belle Beau; Jean-Louis Montastruc; Christine Damase-Michel
Journal:  Pharmacoepidemiol Drug Saf       Date:  2016-03-27       Impact factor: 2.890

7.  Interest of the trajectory method for the evaluation of outcomes after in utero drug exposure: example of anxiolytics and hypnotics.

Authors:  Caroline Hurault-Delarue; Cécile Chouquet; Nicolas Savy; Isabelle Lacroix; Anna-Belle Beau; Jean-Louis Montastruc; Christine Damase-Michel
Journal:  Pharmacoepidemiol Drug Saf       Date:  2017-03-24       Impact factor: 2.890

Review 8.  Safety of newer antidepressants in pregnancy.

Authors:  Cynthia M Way
Journal:  Pharmacotherapy       Date:  2007-04       Impact factor: 4.705

9.  Effect of prenatal selective serotonin reuptake inhibitor (SSRI) exposure on birthweight and gestational age: a sibling-controlled cohort study.

Authors:  Katerina Nezvalová-Henriksen; Olav Spigset; Ragnhild Eek Brandlistuen; Eivind Ystrom; Gideon Koren; Hedvig Nordeng
Journal:  Int J Epidemiol       Date:  2016-12-01       Impact factor: 7.196

Review 10.  Safety of selective serotonin reuptake inhibitors in pregnancy.

Authors:  Sura Alwan; Jan M Friedman
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

View more
  10 in total

1.  Safe Expectations: Current State and Future Directions for Medication Safety in Pregnancy Research.

Authors:  Mollie E Wood; Susan E Andrade; Sengwee Toh
Journal:  Clin Ther       Date:  2019-09-25       Impact factor: 3.393

2.  Oral corticosteroid use during pregnancy and risk of preterm birth.

Authors:  Kristin Palmsten; Gretchen Bandoli; Gabriela Vazquez-Benitez; Min Xi; Diana L Johnson; Ronghui Xu; Christina D Chambers
Journal:  Rheumatology (Oxford)       Date:  2020-06-01       Impact factor: 7.580

3.  Trajectories of Prescription Opioid Utilization During Pregnancy Among Prepregnancy Chronic Users and Risk of Neonatal Opioid Withdrawal Syndrome.

Authors:  Loreen Straub; Krista F Huybrechts; Sonia Hernández-Díaz; Yanmin Zhu; Seanna Vine; Rishi J Desai; Kathryn J Gray; Brian T Bateman
Journal:  Am J Epidemiol       Date:  2022-01-01       Impact factor: 5.363

4.  Patterns of prenatal antidepressant exposure and risk of preeclampsia and postpartum haemorrhage.

Authors:  Kristin Palmsten; Christina D Chambers; Alan Wells; Gretchen Bandoli
Journal:  Paediatr Perinat Epidemiol       Date:  2020-03-24       Impact factor: 3.980

5.  Prenatal Antidepressant Use and Risk of Adverse Neonatal Outcomes.

Authors:  Gretchen Bandoli; Christina D Chambers; Alan Wells; Kristin Palmsten
Journal:  Pediatrics       Date:  2020-06-08       Impact factor: 7.124

6.  Association of Antidepressant Continuation in Pregnancy and Infant Birth Weight.

Authors:  Paige D Wartko; Noel S Weiss; Daniel A Enquobahrie; K C Gary Chan; Alyssa Stephenson-Famy; Beth A Mueller; Sascha Dublin
Journal:  J Clin Psychopharmacol       Date:  2021 Jul-Aug 01       Impact factor: 3.153

Review 7.  Allopregnanolone in postpartum depression: Role in pathophysiology and treatment.

Authors:  Samantha Meltzer-Brody; Stephen J Kanes
Journal:  Neurobiol Stress       Date:  2020-02-03

8.  Prescribing behavior of antidepressants for depressive disorders: A systematic review.

Authors:  Mary K Lam; Lawrence T Lam; Kerryn Butler-Henderson; Jonathan King; Tahnee Clark; Peta Slocombe; Katherine Dimarco; Wendell Cockshaw
Journal:  Front Psychiatry       Date:  2022-09-09       Impact factor: 5.435

9.  Oral Corticosteroids and Risk of Preterm Birth in the California Medicaid Program.

Authors:  Kristin Palmsten; Gretchen Bandoli; Jim Watkins; Gabriela Vazquez-Benitez; Todd P Gilmer; Christina D Chambers
Journal:  J Allergy Clin Immunol Pract       Date:  2020-08-11

Review 10.  Longitudinal Methods for Modeling Exposures in Pharmacoepidemiologic Studies in Pregnancy.

Authors:  Mollie E Wood; Angela Lupattelli; Kristin Palmsten; Gretchen Bandoli; Caroline Hurault-Delarue; Christine Damase-Michel; Christina D Chambers; Hedvig M E Nordeng; Marleen M H J van Gelder
Journal:  Epidemiol Rev       Date:  2022-01-14       Impact factor: 6.222

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.